Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (61-70 of 158) with videos related to

Pageof 16
Sort By:
Cancer|June 7, 2005
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell, John Pippen, Richard M Elledge, et al.
Breast Cancer Research and Treatment|December 3, 2005
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistanceSusan Cleator, Anna Tsimelzon, Alan Ashworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2018
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II TrialMothaffar Rimawi, Jean-Marc Ferrero, Juan de la Haba-Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102Laura F Hutchins, Stephanie J Green, Peter M Ravdin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialAnthony Howell, John F R Robertson, Paul Abram, et al.
Breast Cancer Research and Treatment|November 20, 2009
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, et al.
Breast Cancer Research : BCR|September 3, 2011
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinibCatherine Huang, Catherine C Park, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2023
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final AnalysisGrazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, et al.
Oncogene|October 26, 2002
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growthYongmin Liu, John Ludes-Meyers, Yun Zhang, et al.
Pageof 16

Showing results (61-70 of 158) with videos related to

Sort By:
Pageof 16
Cancer|June 7, 2005
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell, John Pippen, Richard M Elledge, et al.
Breast Cancer Research and Treatment|December 3, 2005
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistanceSusan Cleator, Anna Tsimelzon, Alan Ashworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2018
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II TrialMothaffar Rimawi, Jean-Marc Ferrero, Juan de la Haba-Rodriguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102Laura F Hutchins, Stephanie J Green, Peter M Ravdin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialAnthony Howell, John F R Robertson, Paul Abram, et al.
Breast Cancer Research and Treatment|November 20, 2009
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, et al.
Breast Cancer Research : BCR|September 3, 2011
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinibCatherine Huang, Catherine C Park, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2023
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final AnalysisGrazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, et al.
Oncogene|October 26, 2002
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growthYongmin Liu, John Ludes-Meyers, Yun Zhang, et al.
Pageof 16